U.S. Justice Department's Major Marijuana Reclassification
The U.S. Department of Justice announces the reclassification of FDA-approved and state-licensed marijuana to Schedule III from Schedule I. This move facilitates research and potentially reshapes the cannabis industry by lowering tax burdens and easing funding for cannabis companies, although it doesn't legalize marijuana nationwide.
The U.S. Department of Justice is revising its stance on marijuana, shifting FDA-approved and state-licensed cannabis from a Schedule I to a Schedule III designation, Acting Attorney General Todd Blanche announced.
This action marks a monumental shift in federal marijuana policy, opening doors to crucial research and offering better patient care. It aligns with a previous executive directive by former President Trump to alleviate marijuana restrictions.
This pivotal change is expected to reshape the cannabis industry by reducing tax obligations and easing access to capital, significantly boosting companies like Canopy Growth and Tilray Brands. The announcement immediately propelled U.S.-listed cannabis stocks upward, highlighting investor optimism.
ALSO READ
-
Justice Department watchdog says it is reviewing the department's compliance with law mandating release of Epstein files, reports AP.
-
U.S. DOJ Set to Reshape Marijuana Policy in Landmark Move
-
Historic Marijuana Reform: Legal Landscape Undergoing Major Shift
-
Historic Shift: U.S. Reclassifies Marijuana to Spur Industry Growth
-
Marijuana Reclassification Shakes Up Cannabis Industry
Google News